Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 16/20 | 1.00 |
| ▸ | KCNQ2 | O43526 | 16/20 | 1.00 |
| ▸ | KCNE1 | P15382 | 11/20 | 1.00 |
| ▸ | KCNQ1 | P51787 | 11/20 | 1.00 |
| ▸ | KCNQ5 | Q9NR82 | 6/20 | 1.00 |
| ▸ | MAOB | P27338 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5343768 | 0.90 | KCNQ3 (1.00) | KCNQ3KCNQ2KCNE1KCNQ1KCNQ5 | |
| SCHEMBL14516674 | 0.88 | KCNQ3 (0.81) | KCNQ3KCNQ2KCNE1KCNQ1KCNQ5 | |
| SCHEMBL14516641 | 0.86 | KCNQ3 (0.76) | KCNQ3KCNQ2KCNE1KCNQ1KCNQ5 | |
| SCHEMBL5345718 | 0.86 | KCNQ3 (1.00) | KCNQ3KCNQ2KCNE1KCNQ1KCNQ5 | |
| SCHEMBL14340100 | 0.86 | KCNQ3 (1.00) | KCNQ3KCNQ2KCNE1KCNQ1KCNQ5 | |
| SCHEMBL14516666 | 0.86 | KCNQ3 (0.77) | KCNQ3KCNQ2KCNE1KCNQ1KCNQ5 | |
| SCHEMBL14516690 | 0.85 | KCNQ3 (0.75) | KCNQ3KCNQ2KCNE1KCNQ1KCNQ5 | |
| SCHEMBL14516643 | 0.83 | KCNQ3 (0.77) | KCNQ3KCNQ2KCNE1KCNQ1KCNQ5 | |
| SCHEMBL14516645 | 0.83 | KCNQ3 (0.72) | KCNQ3KCNQ2KCNE1KCNQ1KCNQ5 | |
| SCHEMBL14516672 | 0.82 | KCNQ3 (0.78) | KCNQ3KCNQ2KCNE1KCNQ1KCNQ5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7205307-B2 | Pyrimidines as novel openers of potassium ion channels | ICAGEN, INC. (US) | 2007-04-17 | — | — | US | disclosed |
| US-7205307-B2 | Pyrimidines as novel openers of potassium ion channels | ICAGEN, INC. (US) | 2007-04-17 | — | — | US | disclosed |
| US-7205307-B2 | Pyrimidines as novel openers of potassium ion channels | ICAGEN, INC. (US) | 2007-04-17 | — | — | US | disclosed |
| EP-1483259-A4 | PYRIMIDINES AS NOVEL OPENERS OF POTASSIUM ION CHANNELS | ICAGEN INC (US) | 2005-12-14 | — | — | EP | disclosed |
| EP-1483259-A1 | PYRIMIDINES AS NOVEL OPENERS OF POTASSIUM ION CHANNELS | Icagen, Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20030181465-A1 | Pyrimidines as novel openers of potassium ion channels | ICAGEN, INC. | 2003-09-25 | — | — | US | disclosed |
| WO-2003068767-A1 | PYRIMIDINES AS NOVEL OPENERS OF POTASSIUM ION CHANNELS | ICAGEN, INC. (US) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181465-A1 | Pyrimidines as novel openers of potassium ion channels | KCNJ1, KCNJ2, KCNJ11 | KCNQ3 22/4885KCNQ2 12/4885KCNE1 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.